105 related articles for article (PubMed ID: 8429674)
41. Activation of the MEK/MAPK pathway is involved in bryostatin1-induced monocytic differenciation and up-regulation of X-linked inhibitor of apoptosis protein.
Lin H; Chen C; Li X; Chen BD
Exp Cell Res; 2002 Jan; 272(2):192-8. PubMed ID: 11777344
[TBL] [Abstract][Full Text] [Related]
42. The clinical development of the bryostatins.
Clamp A; Jayson GC
Anticancer Drugs; 2002 Aug; 13(7):673-83. PubMed ID: 12187323
[TBL] [Abstract][Full Text] [Related]
43. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM
Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346
[TBL] [Abstract][Full Text] [Related]
44. Different effects of the two protein kinase C activators bryostatin-1 and TPA on growth and differentiation of human monocytic leukemia cell lines.
Steube KG; Grunicke D; Quentmeier H; Drexler HG
Leuk Res; 1993 Oct; 17(10):897-901. PubMed ID: 8412301
[TBL] [Abstract][Full Text] [Related]
45. Evidence for the biosynthesis of bryostatins by the bacterial symbiont "Candidatus Endobugula sertula" of the bryozoan Bugula neritina.
Davidson SK; Allen SW; Lim GE; Anderson CM; Haygood MG
Appl Environ Microbiol; 2001 Oct; 67(10):4531-7. PubMed ID: 11571152
[TBL] [Abstract][Full Text] [Related]
46. Co-induction of lymphokine synthesis by the antineoplastic bryostatins.
Mohr H; Pettit GR; Plessing-Menze A
Immunobiology; 1987 Nov; 175(5):420-30. PubMed ID: 3123367
[TBL] [Abstract][Full Text] [Related]
47. Effect of bryostatin 1 on the in vitro radioprotective capacity of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) toward committed human myeloid progenitor cells (CFU-GM).
Grant S; Pettit GR; McCrady C
Exp Hematol; 1992 Jan; 20(1):34-42. PubMed ID: 1374343
[TBL] [Abstract][Full Text] [Related]
48. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity.
Wang H; Mohammad RM; Werdell J; Shekhar PV
Int J Mol Med; 1998 Jun; 1(6):915-23. PubMed ID: 9852625
[TBL] [Abstract][Full Text] [Related]
49. Effects of bryostatins 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells.
Jalava AM; Heikkilä J; Akerlind G; Pettit GR; Akerman KE
Cancer Res; 1990 Jun; 50(11):3422-8. PubMed ID: 2334938
[TBL] [Abstract][Full Text] [Related]
50. Mimicry of bryostatin 1 induced phosphorylation patterns in HL-60 cells by high-phorbol ester concentrations.
Warren BS; Kamano Y; Pettit GR; Blumberg PM
Cancer Res; 1988 Nov; 48(21):5984-8. PubMed ID: 3167850
[TBL] [Abstract][Full Text] [Related]
51. Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors.
Thijsen SF; Schuurhuis GJ; van Oostveen JW; Theijsmeijer AP; van der Hem KG; Odding JH; Dräger AM; Ossenkoppele GJ
Br J Cancer; 1999 Mar; 79(9-10):1406-12. PubMed ID: 10188883
[TBL] [Abstract][Full Text] [Related]
52. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Eilender DS; Hulburd K; Rodriguez DH; Pemberton PA; Pluda JM; Dan MD; Pettit GR; Chen BD; Al-Katib AM
J Clin Oncol; 1998 Jan; 16(1):56-62. PubMed ID: 9440723
[TBL] [Abstract][Full Text] [Related]
53. Effects of bryostatin 1 and calcium ionophore (A23187) on apoptosis and differentiation in human myeloid leukemia cells (HL-60) following 1-beta-D-arabinofuranosylcytosine exposure.
Vrana JA; Rao AS; Wang Z; Jarvis WD; Grant S
Int J Oncol; 1998 Apr; 12(4):927-34. PubMed ID: 9499457
[TBL] [Abstract][Full Text] [Related]
54. Synergistic action of calcium ionophore A23187 and protein kinase C activator bryostatin 1 on human B cell activation and proliferation.
Drexler HG; Gignac SM; Pettit GR; Hoffbrand AV
Eur J Immunol; 1990 Jan; 20(1):119-27. PubMed ID: 1689659
[TBL] [Abstract][Full Text] [Related]
55. Bryostatin 1: differentiating agent from the depths.
Stone RM
Leuk Res; 1997 May; 21(5):399-401. PubMed ID: 9225066
[No Abstract] [Full Text] [Related]
56. Effects of bryostatin-5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency.
van der Hem KG; Dräger AM; Odding JH; Huijgens PC
Leuk Res; 1995 Sep; 19(9):651-7. PubMed ID: 7564476
[TBL] [Abstract][Full Text] [Related]
57. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.
Blackhall FH; Ranson M; Radford JA; Hancock BW; Soukop M; McGown AT; Robbins A; Halbert G; Jayson GC;
Br J Cancer; 2001 Feb; 84(4):465-9. PubMed ID: 11263437
[TBL] [Abstract][Full Text] [Related]
58. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD
Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972
[TBL] [Abstract][Full Text] [Related]
59. Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms.
Wojciechowski W; Li H; Marshall S; Dell'Agnola C; Espinoza-Delgado I
J Immunol; 2005 Jun; 174(12):7859-68. PubMed ID: 15944291
[TBL] [Abstract][Full Text] [Related]
60. The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C.
Hood KA; Bäckström BT; West LM; Northcote PT; Berridge MV; Miller JH
Anticancer Drug Des; 2001; 16(2-3):155-66. PubMed ID: 11962513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
